You are here

DISCOVERYBIOMED, INC.

Company Information
Address
400 Riverhills Business Park
BIRMINGHAM, AL 35242-5038
United States


http://www.discoverybiomed.com

Information

UEI: LR7QH452JJ31

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Broad Spectrum Bitter Taste Antagonists Discovery

    Amount: $1,602,197.00

    Principal Investigators for Small Business: DiscoveryBioMed, Inc. (DBM) and Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming ...

    STTRPhase II2020Department of Health and Human Services National Institutes of Health
  2. STING Inhibitor Discovery for Rare and Common Autoimmune Diseases

    Amount: $300,000.00

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Nitor TherapeuticsIncNitorProject Summary Abstract The over arching commercial goal for this Nitor TherapeuticsIncNitorand DiscoveryB ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. Humanized Kidney Cellular Toxicity Platforms

    Amount: $1,073,852.00

    The over arching goal of this proposed SBIR driven program is to create relevant DiscoveryBioMedDBMhuman cellular toxicityHCTplatforms for the kidney grown inD and inD cell culture formats for a newgo ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  4. Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery

    Amount: $286,536.00

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global pu ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia

    Amount: $838,880.00

    DiscoveryBioMedIncDBMIncor DBMspecializes in normal and diseased human cell platform engineeringDBM has assembled a consortium of expertswherebycollectivelywe seek Fast Track SBIR funding to establish ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  6. Humanized Kidney Cellular Toxicity Platforms

    Amount: $206,210.00

    Principal Investigators for Small Business DiscoveryBioMed Inc DBM Project Summary Abstract The over arching goal of this proposed SBIR driven program is to create relevant DiscoveryBioMed DBM ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  7. Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia

    Amount: $366,185.00

    DESCRIPTION provided by applicant DiscoveryBioMed Inc DBM Inc or DBM specializes in normal and diseased human cell platform engineering DBM has assembled a consortium of experts whereby co ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  8. Adiponectin Secretion Enhancer Synthetic Organic Drug Discovery and Development

    Amount: $1,613,420.00

    DESCRIPTION provided by applicant DiscoveryBioMed Inc DBM completed recently Phase I SBIR funded goals milestones specific experimental aims and efforts to screen synthetic organic sma ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  9. Chronically Acting CFTR Inhibitor Discovery for Secretory Diarrhea and ADPKD

    Amount: $224,700.00

    Project Summary Abstract DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen a collection of small molecular compounds on a human epithelial ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  10. DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease

    Amount: $1,135,118.00

    DESCRIPTION provided by applicant An important discovery and validation event occurred recently within human cell based drug discovery programs at DiscoveryBioMed Inc DBM yielding a lead clas ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government